← Leaderboards
Xiuli Wang
Beckman Research Institute/City Of Hope
$2,702,470
Attributed
$7,898,472
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,898,472 · 4
By mechanism
R01$7,898,472 · 4
Top collaborators
- Flavia Pichiorri5 shared
- Russell Christian Rockne5 shared
- John E. Shively5 shared
- Ibrahim Aldoss4 shared
- Stephen J Forma4 shared
- Tanya Siddiqi4 shared
- Larry W Kwak3 shared
- Ryotaro Nakamura1 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Hua E Yu$13,108,796
- Sunita K Patel$3,987,029
- Hsun Teresa Ku$4,643,245
- Sophia S. Wang$9,836,949
- Russell Christian Rockne$4,281,270
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneChimeric Antigen Receptor T CellsCar T Cell TherapyIn VivoRelapseMouse ModelFda ApprovedTargeted TreatmentReportingDoseResistanceT-LymphocyteChimeric Antigen ReceptorCellsRegimenNon-Hodgkin&AposMalignant NeoplasmsCitiesKineticsHematologic NeoplasmsLymphomaCell PhysiologyCd19 GeneEpitopes
Grant awards (14)
CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL$738,698
R01 · FY2025 · CA · contact PI
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$710,483
R01 · FY2025 · CA · contact PI
BAFF-R CAR T cell therapy for ALL$677,623
R01 · FY2025 · CA · contact PI
BAFF-R CAR T cell therapy for ALL$643,742
R01 · FY2024 · CA
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$364,612
R01 · FY2024 · CA · contact PI
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$705,167
R01 · FY2023 · CA · contact PI
BAFF-R CAR T cell therapy for ALL$664,070
R01 · FY2023 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2023 · CA
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma$719,558
R01 · FY2022 · CA · contact PI
BAFF-R CAR T cell therapy for ALL$677,623
R01 · FY2022 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2022 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2021 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2020 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2019 · CA